Based on the findings, it was concluded that fluconazole use during pregnancy was not associated with significantly increased risks of stillbirth or neonatal death. However, the authors cautioned that the confidence intervals were wide and neither result was statistically significant.
Although rare even in high-risk groups, invasive aspergillosis is associated with high hospital mortality rates, excess duration of hospitalization, and a 40% relative increase in the odds of 30-day readmission.
While isavuconazole is an important therapeutic option in the management of invasive fungal infections, the epidemiology and microbiology of breakthrough infections on this agent are not well understood.
The absence of availability of amphotericin B or in conditions in which amphotericin B cannot be administered safely, the oral combination of fluconazole plus flucytosine provides an effective and sustainable alternative.